Macular Degeneration, Age-Related, Neovascularization, Choroidal
Conditions
Brief summary
This was a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in treatment-naive participants with neovascular age related macular degeneration (nAMD). Only one eye was chosen as the study eye.
Interventions
DRUGFaricimab
Faricimab was administered via IVT injections as specified during the treatment period.
DRUGRanibizumab
Ranibizumab was administered via IVT injections as specified during the treatment period.
DRUGSham Procedure
The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Treatment-naive CNV secondary to AMD (nAMD) * Subfoveal or juxtafoveal CNV with a subfoveal component related to the CNV activity by fundus fluorescein angiography (FFA) or spectral-domain optical coherence tomography (SD-OCT; as evidenced by subretinal fluid, subretinal hyperreflective material, evidence of leakage, or hemorrhage) * CNV lesion of all types with: total lesion size (including blood, atrophy, fibrosis, and neovascularization) of 6 disc areas or less by FFA; and CNV component area of at least 50% of total lesion size by FFA; and active CNV confirmed by FFA (evidence of leakage); and CNV exudation confirmed by SD-OCT (presence of fluid) * BCVA letter score of 73 to 24 letters (inclusive) on ETDRS-like charts (20/40-20/320 Snellen equivalent) on day 1 * Clear ocular media and adequate pupillary dilatation to allow acquisition of good-quality retinal images to confirm diagnosis
Exclusion criteria
* CNV due to causes other than AMD, such as ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, or uveitis * Central serous chorioretinopathy at screening * Retinal pigment epithelial tear involving the macula * On FFA: subretinal hemorrhage, fibrosis, or atrophy of more than (\>)50% of the total lesion area and/or that involves the fovea * Any prior or concomitant treatment for CNV including (but not restricted to) IVT treatment (steroids, anti-VEGF, tissue plasminogen activator, ocriplasmin, C3F8 gas, air), periocular pharmacological intervention, argon laser photocoagulation, verteporfin photodynamic therapy, diode laser, transpupillary thermotherapy, or surgical intervention * Cataract surgery within 3 months of baseline assessments * Any other intraocular surgery (pars plana vitrectomy, glaucoma surgery, corneal transplant, radiotherapy) * Prior IVT treatment (including anti-VEGF medication) except for management of cataract complication with steroid IVT treatment * Prior periocular pharmacological intervention for other retinal diseases * Any concurrent intraocular condition in the study eye (eg, amblyopia, aphakia, retinal detachment, cataract, diabetic retinopathy or maculopathy, or epiretinal membrane with traction) that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the course of the study * Active intraocular inflammation (grade trace or above) in the study eye on day 1 (before randomization) * Current vitreous hemorrhage in the study eye * Uncontrolled glaucoma (eg, progressive loss of visual fields or defined as IOP ≥25 mm Hg despite treatment with antiglaucoma medication) in the study eye * Spherical equivalent of refractive error demonstrating more than 8 diopters of myopia in the study eye * History of idiopathic or autoimmune-associated uveitis in either eye * Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye on day 1 (before randomization) * Any major illness or major surgical procedure within 1 month before screening * Uncontrolled blood pressure (defined as systolic \>180 mm Hg and/or diastolic \>100 mm Hg while participant at rest). If a participant's initial reading exceeded these values, a second reading was taken later on the same day, or on another day during the screening period. If the participant's blood pressure was controlled by antihypertensive medication, the participant was taking the same medication continuously for at least 30 days before day 1 * Stroke or myocardial infarction within 3 months before day 1 * History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory findings giving reasonable suspicion of a condition that contraindicated the use of the investigational drug or that might affect interpretation of the results of the study or renders the participant at high risk for treatment complications in the opinion of the investigator * Pregnant or breastfeeding, or intended to become pregnant during the study * Known hypersensitivity to ranibizumab, fluorescein, any ingredients of the formulation used, dilating eye drops, or any of the anesthetic and antimicrobial drops used * Treatment with investigational therapy within 3 months before initiation of study treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts | Baseline, Week 40 | Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. |
| Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method. |
| Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a loss in BCVA letter score from baseline indicates worsening in visual acuity. This analysis was performed on observed data. |
| Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method. |
| Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method. |
| Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method. |
| Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | Central foveal thickness (CFT) was defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CFT. |
| Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | Central subfield thickness (CST) was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CST. |
| Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA. |
| Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method. |
| Percentage of Participants With No Cysts at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method. |
| Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method. |
| Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52 | Baseline, Week 40, Week 52 | The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA). |
| Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52 | Baseline, Week 40, Week 52 | The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA). |
| Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52 | Baseline, Week 40, Week 52 | The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA). |
| Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline | Predose at Baseline (Day 1), Weeks 16, 24, 28, 44, and 52 | Blood samples were obtained for measurement of anti-drug antibodies (ADAs) to faricimab by a validated enzyme-linked immunosorbent assay (ELISA). |
| Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | From Baseline until 28 days after the last dose of study drug (up to 52 weeks) | This safety summary reports the number and percentage of participants who experienced at least one adverse event (AE) during the study. The investigator independently assessed the seriousness and severity for each AE. Severity was graded according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Severity and seriousness are not synonymous; regardless of severity, some AEs may have also met seriousness criteria. |
| Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Intraretinal fluid was defined as the presence of fluid within the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 6 mg Faricimab Q12W 6 mg faricimab was given by intravitreal (IVT) injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by 6 mg faricimab IVT injection once every 12 weeks (Q12W) from Week 24 up to Week 48 (injections at Weeks 24, 36, and 48; 3 injections). | 24 |
| 6 mg Faricimab Q16W 6 mg faricimab was administered by IVT injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by no doses up to Week 24 when a protocol-defined assessment of disease activity was performed. Participants with disease activity at Week 24 initiated 6 mg faricimab IVT Q12W dosing, and participants without disease activity at Week 24 initiated 6 mg faricimab IVT once every 16 weeks (Q16W) dosing for the remainder of the study. | 31 |
| 0.5 mg Ranibizumab Q4W 0.5 mg of ranibizumab was administered by IVT injection once every 4 weeks (Q4W) for 48 weeks (13 injections). | 16 |
| Total | 71 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 1 | 2 | 0 |
| Overall Study | Physician Decision | 2 | 1 | 0 |
Baseline characteristics
| Characteristic | Total | 6 mg Faricimab Q12W | 0.5 mg Ranibizumab Q4W | 6 mg Faricimab Q16W |
|---|---|---|---|---|
| Age, Continuous | 78.5 Years STANDARD_DEVIATION 8.47 | 80.3 Years STANDARD_DEVIATION 7.23 | 77.3 Years STANDARD_DEVIATION 10.29 | 77.7 Years STANDARD_DEVIATION 8.38 |
| Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye at Baseline | 58.4 ETDRS Letters STANDARD_DEVIATION 11.02 | 57.8 ETDRS Letters STANDARD_DEVIATION 10.46 | 55.3 ETDRS Letters STANDARD_DEVIATION 12.08 | 60.4 ETDRS Letters STANDARD_DEVIATION 10.8 |
| Central Foveal Thickness in the Study Eye at Baseline | 305.6 microns (μm) STANDARD_DEVIATION 125.42 | 290.8 microns (μm) STANDARD_DEVIATION 118.61 | 375.6 microns (μm) STANDARD_DEVIATION 159.41 | 280.8 microns (μm) STANDARD_DEVIATION 98.95 |
| Central Subfield Thickness in the Study Eye at Baseline | 408.0 microns (μm) STANDARD_DEVIATION 95.36 | 417.9 microns (μm) STANDARD_DEVIATION 84.28 | 443.1 microns (μm) STANDARD_DEVIATION 125 | 382.2 microns (μm) STANDARD_DEVIATION 80.87 |
| Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline Classic and Occult CNV | 4 Participants | 0 Participants | 2 Participants | 2 Participants |
| Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline Classic CNV | 24 Participants | 9 Participants | 6 Participants | 9 Participants |
| Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline Occult CNV | 43 Participants | 15 Participants | 8 Participants | 20 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 70 Participants | 23 Participants | 16 Participants | 31 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Black or African American | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White | 69 Participants | 23 Participants | 16 Participants | 30 Participants |
| Sex: Female, Male Female | 41 Participants | 13 Participants | 10 Participants | 18 Participants |
| Sex: Female, Male Male | 30 Participants | 11 Participants | 6 Participants | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 24 | 2 / 31 | 0 / 16 |
| other Total, other adverse events | 18 / 24 | 22 / 31 | 13 / 16 |
| serious Total, serious adverse events | 4 / 24 | 3 / 31 | 0 / 16 |
Outcome results
Primary
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA.
Time frame: Baseline, Week 40
Population: Efficacy population: participants grouped according to their assigned treatment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| 6 mg Faricimab Q12W | Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts | 9.3 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts | 12.5 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts | 11.4 ETDRS Letters |
80% CI: [-6.8, 2.6]
80% CI: [-3.4, 5.5]
Secondary
Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline
Blood samples were obtained for measurement of anti-drug antibodies (ADAs) to faricimab by a validated enzyme-linked immunosorbent assay (ELISA).
Time frame: Predose at Baseline (Day 1), Weeks 16, 24, 28, 44, and 52
Population: Safety Population: participants who received at least one dose of study treatment, grouped according to treatment received. The analysis only included participants who received treatment with faricimab (i.e., 0.5 mg Ranibizumab Q4W arm was excluded) and had evaluable samples at baseline and/or any post-baseline timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline | ADA Negative to ADA Positive | 1 Participants |
| 6 mg Faricimab Q12W | Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline | Missing to ADA Positive | 1 Participants |
| 6 mg Faricimab Q12W | Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline | ADA Negative to ADA Negative | 21 Participants |
| 6 mg Faricimab Q12W | Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline | No Post-Baseline ADA Assessment | 1 Participants |
| 6 mg Faricimab Q12W | Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline | Missing to ADA Negative | 0 Participants |
| 6 mg Faricimab Q16W | Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline | No Post-Baseline ADA Assessment | 1 Participants |
| 6 mg Faricimab Q16W | Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline | ADA Negative to ADA Negative | 25 Participants |
| 6 mg Faricimab Q16W | Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline | ADA Negative to ADA Positive | 4 Participants |
| 6 mg Faricimab Q16W | Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline | Missing to ADA Negative | 1 Participants |
| 6 mg Faricimab Q16W | Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline | Missing to ADA Positive | 0 Participants |
Secondary
Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52
The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA).
Time frame: Baseline, Week 40, Week 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| 6 mg Faricimab Q12W | Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52 | Change from BL at Week 52 | -5.4 millimetres squared (mm^2) | Standard Deviation 4 |
| 6 mg Faricimab Q12W | Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52 | Change from BL at Week 40 | -4.7 millimetres squared (mm^2) | Standard Deviation 4.3 |
| 6 mg Faricimab Q12W | Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52 | Baseline (BL): Absolute Value | 7.1 millimetres squared (mm^2) | Standard Deviation 3.9 |
| 6 mg Faricimab Q16W | Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52 | Change from BL at Week 40 | -3.9 millimetres squared (mm^2) | Standard Deviation 3.7 |
| 6 mg Faricimab Q16W | Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52 | Baseline (BL): Absolute Value | 5.9 millimetres squared (mm^2) | Standard Deviation 3.8 |
| 6 mg Faricimab Q16W | Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52 | Change from BL at Week 52 | -4.2 millimetres squared (mm^2) | Standard Deviation 3.4 |
| 0.5 mg Ranibizumab Q4W | Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52 | Baseline (BL): Absolute Value | 7.3 millimetres squared (mm^2) | Standard Deviation 2.9 |
| 0.5 mg Ranibizumab Q4W | Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52 | Change from BL at Week 52 | -4.5 millimetres squared (mm^2) | Standard Deviation 3.2 |
| 0.5 mg Ranibizumab Q4W | Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52 | Change from BL at Week 40 | -4.6 millimetres squared (mm^2) | Standard Deviation 3.5 |
Secondary
Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52
The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA).
Time frame: Baseline, Week 40, Week 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| 6 mg Faricimab Q12W | Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52 | Change from BL at Week 40 | -5.0 millimetres squared (mm^2) | Standard Deviation 4.2 |
| 6 mg Faricimab Q12W | Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52 | Baseline (BL): Absolute Value | 7.0 millimetres squared (mm^2) | Standard Deviation 3.8 |
| 6 mg Faricimab Q12W | Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52 | Change from BL at Week 52 | -5.6 millimetres squared (mm^2) | Standard Deviation 4 |
| 6 mg Faricimab Q16W | Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52 | Change from BL at Week 40 | -4.0 millimetres squared (mm^2) | Standard Deviation 4 |
| 6 mg Faricimab Q16W | Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52 | Baseline (BL): Absolute Value | 5.8 millimetres squared (mm^2) | Standard Deviation 3.6 |
| 6 mg Faricimab Q16W | Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52 | Change from BL at Week 52 | -4.3 millimetres squared (mm^2) | Standard Deviation 3.7 |
| 0.5 mg Ranibizumab Q4W | Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52 | Baseline (BL): Absolute Value | 7.1 millimetres squared (mm^2) | Standard Deviation 3 |
| 0.5 mg Ranibizumab Q4W | Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52 | Change from BL at Week 52 | -4.8 millimetres squared (mm^2) | Standard Deviation 3.2 |
| 0.5 mg Ranibizumab Q4W | Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52 | Change from BL at Week 40 | -4.7 millimetres squared (mm^2) | Standard Deviation 3.4 |
Secondary
Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52
The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA).
Time frame: Baseline, Week 40, Week 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| 6 mg Faricimab Q12W | Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52 | Change from BL at Week 40 | -5.0 millimetres squared (mm^2) | Standard Deviation 4.2 |
| 6 mg Faricimab Q12W | Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52 | Baseline (BL): Absolute Value | 7.0 millimetres squared (mm^2) | Standard Deviation 3.8 |
| 6 mg Faricimab Q12W | Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52 | Change from BL at Week 52 | -5.6 millimetres squared (mm^2) | Standard Deviation 4 |
| 6 mg Faricimab Q16W | Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52 | Change from BL at Week 40 | -4.3 millimetres squared (mm^2) | Standard Deviation 3.9 |
| 6 mg Faricimab Q16W | Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52 | Baseline (BL): Absolute Value | 6.1 millimetres squared (mm^2) | Standard Deviation 3.4 |
| 6 mg Faricimab Q16W | Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52 | Change from BL at Week 52 | -4.6 millimetres squared (mm^2) | Standard Deviation 3.5 |
| 0.5 mg Ranibizumab Q4W | Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52 | Baseline (BL): Absolute Value | 7.6 millimetres squared (mm^2) | Standard Deviation 2.9 |
| 0.5 mg Ranibizumab Q4W | Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52 | Change from BL at Week 52 | -5.3 millimetres squared (mm^2) | Standard Deviation 3.5 |
| 0.5 mg Ranibizumab Q4W | Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52 | Change from BL at Week 40 | -5.3 millimetres squared (mm^2) | Standard Deviation 3.7 |
Secondary
Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 36 | 9.01 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 16 | 8.31 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 32 | 9.87 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 28 | 9.59 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 44 | 9.38 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 20 | 8.02 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 52 | 10.08 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 24 | 8.11 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 4 | 5.99 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 48 | 9.53 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 8 | 5.28 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 40 | 9.33 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 12 | 7.31 ETDRS Letters |
| 6 mg Faricimab Q12W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Day 7 | 3.78 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 16 | 11.62 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 44 | 12.07 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Day 7 | 4.62 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 4 | 7.55 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 8 | 9.15 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 12 | 10.19 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 40 | 12.47 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 20 | 10.40 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 24 | 10.37 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 28 | 11.82 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 32 | 12.44 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 36 | 12.38 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 48 | 10.99 ETDRS Letters |
| 6 mg Faricimab Q16W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 52 | 11.42 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 40 | 11.42 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 44 | 11.22 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 32 | 11.91 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 12 | 9.91 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 52 | 9.59 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 36 | 12.03 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 8 | 10.55 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 4 | 7.53 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 20 | 11.53 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 48 | 10.22 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 24 | 10.97 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 16 | 10.78 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Day 7 | 3.53 ETDRS Letters |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts | Week 28 | 12.16 ETDRS Letters |
Comparison: Week 40: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [-6.75, 2.56]
Comparison: Week 40: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-3.4, 5.49]
Comparison: Week 52: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [-4.26, 5.25]
Comparison: Week 52: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-2.71, 6.37]
Secondary
Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints
Central foveal thickness (CFT) was defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CFT.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 40 | -137.54 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 20 | -125.05 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 8 | -134.47 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 36 | -114.27 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 24 | -121.13 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 4 | -132.27 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 32 | -127.85 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 28 | -131.58 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 44 | -135.30 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 12 | -142.26 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 52 | -140.95 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Day 7 | -93.56 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 16 | -134.94 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 48 | -125.93 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 40 | -123.31 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Day 7 | -94.31 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 4 | -130.11 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 8 | -136.15 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 12 | -139.63 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 16 | -137.81 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 20 | -125.35 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 24 | -108.66 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 28 | -116.76 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 32 | -123.44 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 36 | -114.97 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 44 | -110.26 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 48 | -121.67 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 52 | -134.99 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 48 | -130.76 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 36 | -149.26 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 16 | -120.48 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 12 | -126.63 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 40 | -137.99 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 8 | -127.64 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Day 7 | -76.01 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 44 | -135.70 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 4 | -122.07 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 28 | -130.29 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 24 | -131.29 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 52 | -136.10 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 32 | -134.29 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints | Week 20 | -120.70 microns (μm) |
Comparison: Week 40: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [-29.81, 30.71]
Comparison: Week 40: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-14.29, 43.65]
Comparison: Week 52: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [-30.57, 20.87]
Comparison: Week 52: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-23.57, 25.8]
Secondary
Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints
Central subfield thickness (CST) was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CST.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 40 | -138.55 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 20 | -114.97 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 8 | -132.03 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 36 | -101.98 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 24 | -101.62 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 4 | -127.20 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 32 | -121.10 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 28 | -129.68 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 44 | -130.50 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 12 | -134.70 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 52 | -138.53 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Day 7 | -88.87 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 16 | -132.96 microns (μm) |
| 6 mg Faricimab Q12W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 48 | -126.45 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 40 | -121.34 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Day 7 | -84.23 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 4 | -123.10 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 8 | -131.25 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 12 | -132.87 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 16 | -132.50 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 20 | -118.89 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 24 | -99.35 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 28 | -109.89 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 32 | -116.35 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 36 | -102.69 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 44 | -103.31 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 48 | -102.30 microns (μm) |
| 6 mg Faricimab Q16W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 52 | -122.53 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 48 | -123.89 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 36 | -118.89 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 16 | -122.70 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 12 | -122.39 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 40 | -126.32 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 8 | -117.04 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Day 7 | -80.08 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 44 | -124.89 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 4 | -111.58 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 28 | -127.95 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 24 | -121.33 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 52 | -129.89 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 32 | -127.20 microns (μm) |
| 0.5 mg Ranibizumab Q4W | Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints | Week 20 | -120.77 microns (μm) |
Comparison: Week 40: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [-36.6, 12.15]
Comparison: Week 40: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-18.5, 28.45]
Comparison: Week 52: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [-30.42, 13.14]
Comparison: Week 52: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-13.65, 28.37]
Secondary
Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥15 Letters | 7 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥5 Letters | 16 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥5 Letters | 11 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥0 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥0 Letters | 21 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥5 Letters | 15 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥15 Letters | 4 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥15 Letters | 1 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥10 Letters | 11 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥10 Letters | 9 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥10 Letters | 7 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥5 Letters | 15 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥15 Letters | 3 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥0 Letters | 19 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥0 Letters | 19 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥0 Letters | 17 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥5 Letters | 15 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥15 Letters | 6 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥5 Letters | 14 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥10 Letters | 10 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥10 Letters | 2 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥5 Letters | 16 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥5 Letters | 14 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥15 Letters | 7 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥0 Letters | 21 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥0 Letters | 22 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥15 Letters | 7 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥10 Letters | 13 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥5 Letters | 17 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥10 Letters | 11 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥10 Letters | 11 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥15 Letters | 2 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥10 Letters | 5 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥15 Letters | 7 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥10 Letters | 8 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥15 Letters | 8 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥0 Letters | 18 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥5 Letters | 15 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥5 Letters | 15 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥0 Letters | 19 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥10 Letters | 12 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥15 Letters | 4 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥5 Letters | 15 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥10 Letters | 10 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥15 Letters | 7 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥5 Letters | 16 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥0 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥0 Letters | 15 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥0 Letters | 21 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥15 Letters | 3 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥5 Letters | 13 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥15 Letters | 4 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥0 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥10 Letters | 12 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥10 Letters | 10 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥0 Letters | 17 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥5 Letters | 20 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥5 Letters | 16 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥0 Letters | 26 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥15 Letters | 4 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥10 Letters | 8 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥5 Letters | 19 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥0 Letters | 30 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥15 Letters | 5 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥10 Letters | 10 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥5 Letters | 26 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥0 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥15 Letters | 7 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥10 Letters | 16 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥0 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥15 Letters | 9 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥5 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥0 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥15 Letters | 10 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥10 Letters | 17 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥5 Letters | 22 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥0 Letters | 26 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥15 Letters | 8 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥10 Letters | 16 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥5 Letters | 22 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥0 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥15 Letters | 12 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥10 Letters | 15 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥5 Letters | 24 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥0 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥15 Letters | 11 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥5 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥0 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥15 Letters | 11 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥10 Letters | 20 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥5 Letters | 24 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥0 Letters | 25 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥10 Letters | 18 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥5 Letters | 24 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥15 Letters | 13 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥10 Letters | 15 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥5 Letters | 26 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥0 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥15 Letters | 10 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥10 Letters | 17 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥0 Letters | 26 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥15 Letters | 13 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥10 Letters | 17 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥5 Letters | 23 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥0 Letters | 26 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥15 Letters | 2 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥10 Letters | 4 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥5 Letters | 23 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥10 Letters | 16 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥10 Letters | 18 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥15 Letters | 11 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥0 Letters | 27 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥5 Letters | 8 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥15 Letters | 6 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥15 Letters | 3 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥5 Letters | 6 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥10 Letters | 9 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥0 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥10 Letters | 5 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥5 Letters | 11 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥5 Letters | 13 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥15 Letters | 3 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Gaining ≥0 Letters | 13 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Gaining ≥10 Letters | 8 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥15 Letters | 1 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥15 Letters | 6 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥0 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥5 Letters | 14 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥10 Letters | 10 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥5 Letters | 11 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥5 Letters | 11 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥10 Letters | 7 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥10 Letters | 9 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Gaining ≥0 Letters | 12 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Gaining ≥15 Letters | 3 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥15 Letters | 3 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥15 Letters | 6 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥0 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥10 Letters | 9 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥10 Letters | 9 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥5 Letters | 10 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥0 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥15 Letters | 6 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥5 Letters | 9 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥5 Letters | 11 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥0 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥10 Letters | 8 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥0 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥5 Letters | 11 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Gaining ≥10 Letters | 1 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥15 Letters | 6 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Gaining ≥15 Letters | 5 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Gaining ≥0 Letters | 13 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥10 Letters | 10 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥0 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Gaining ≥15 Letters | 6 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥5 Letters | 12 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥5 Letters | 12 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Gaining ≥10 Letters | 9 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥15 Letters | 5 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Gaining ≥15 Letters | 4 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Gaining ≥0 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥10 Letters | 8 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥0 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Gaining ≥0 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥5 Letters | 10 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Gaining ≥0 Letters | 13 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Gaining ≥10 Letters | 9 Participants |
Secondary
Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a loss in BCVA letter score from baseline indicates worsening in visual acuity. This analysis was performed on observed data.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥5 Letters | 22 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥5 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥10 Letters | 21 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥0 Letters | 19 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥10 Letters | 24 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥15 Letters | 21 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥15 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥10 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥0 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥10 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥0 Letters | 18 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥5 Letters | 22 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥5 Letters | 22 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥5 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥10 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥0 Letters | 19 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥15 Letters | 21 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥15 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥15 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥15 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥0 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥10 Letters | 22 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥5 Letters | 21 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥5 Letters | 21 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥5 Letters | 22 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥0 Letters | 14 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥10 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥0 Letters | 19 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥10 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥15 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥10 Letters | 21 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥5 Letters | 17 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥5 Letters | 22 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥0 Letters | 18 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥10 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥0 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥15 Letters | 21 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥15 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥15 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥15 Letters | 24 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥0 Letters | 17 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥10 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥0 Letters | 16 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥5 Letters | 19 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥5 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥0 Letters | 16 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥10 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥0 Letters | 19 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥10 Letters | 24 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥15 Letters | 20 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥15 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥15 Letters | 24 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥0 Letters | 19 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥10 Letters | 23 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥5 Letters | 19 Participants |
| 6 mg Faricimab Q12W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥5 Letters | 20 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥10 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥10 Letters | 31 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥0 Letters | 24 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥15 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥10 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥5 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥15 Letters | 31 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥10 Letters | 31 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥5 Letters | 31 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥0 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥15 Letters | 30 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥10 Letters | 30 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥5 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥0 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥15 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥10 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥5 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥0 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥15 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥10 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥5 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥0 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥15 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥10 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥5 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥0 Letters | 24 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥15 Letters | 30 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥10 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥5 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥0 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥15 Letters | 29 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥10 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥5 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥0 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥10 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥5 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥0 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥15 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥10 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥5 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥0 Letters | 25 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥15 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥15 Letters | 31 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥5 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥0 Letters | 25 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥15 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥10 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥5 Letters | 28 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥0 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥15 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥5 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥0 Letters | 25 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥15 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥10 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥5 Letters | 27 Participants |
| 6 mg Faricimab Q16W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥0 Letters | 26 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥5 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥5 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥15 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥5 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥0 Letters | 14 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥0 Letters | 14 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥15 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥15 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥5 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥0 Letters | 11 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥10 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥0 Letters | 11 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥5 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 12: Not Losing ≥15 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥0 Letters | 10 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 40: Not Losing ≥0 Letters | 12 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥0 Letters | 13 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥5 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥15 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥5 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥15 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥10 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥5 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥5 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥0 Letters | 14 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 8: Not Losing ≥15 Letters | 15 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥15 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥5 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Day 7: Not Losing ≥15 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 44: Not Losing ≥0 Letters | 12 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥5 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 24: Not Losing ≥15 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥0 Letters | 13 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 28: Not Losing ≥0 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥0 Letters | 14 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥15 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥5 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 52: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥15 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥5 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 20: Not Losing ≥15 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 4: Not Losing ≥5 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 32: Not Losing ≥0 Letters | 13 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 16: Not Losing ≥0 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 48: Not Losing ≥10 Letters | 16 Participants |
| 0.5 mg Ranibizumab Q4W | Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints | Week 36: Not Losing ≥15 Letters | 16 Participants |
Secondary
Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 12 | 8.7 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 44 | 35.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 4 | 12.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 48 | 33.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 16 | 17.4 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 52 | 33.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Day 7 | 4.2 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 20 | 17.4 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 24 | 17.4 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 8 | 12.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 28 | 26.1 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 32 | 30.4 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 36 | 31.8 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 40 | 38.1 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 28 | 40.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 40 | 39.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 12 | 23.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 20 | 33.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 44 | 44.8 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Day 7 | 6.5 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 36 | 37.9 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 48 | 35.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 24 | 26.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 32 | 36.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 16 | 30.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 52 | 46.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 4 | 12.9 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 8 | 16.7 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 28 | 31.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Day 7 | 6.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 4 | 18.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 12 | 18.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 16 | 18.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 20 | 18.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 24 | 25.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 32 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 36 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 40 | 33.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 44 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 48 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 52 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 8 | 40.0 Percentage of participants |
Comparison: Week 40: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [-15.92, 25.44]
Comparison: Week 40: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-13.62, 25.53]
Comparison: Week 52: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [-24.52, 16.19]
Comparison: Week 52: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-10.73, 28.59]
Secondary
Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 40 | 95.2 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 20 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 8 | 95.8 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 36 | 95.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 24 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 4 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 32 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 28 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 44 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 12 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 52 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Day 7 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 16 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 48 | 100.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 40 | 96.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Day 7 | 100.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 4 | 100.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 8 | 100.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 12 | 96.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 16 | 96.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 20 | 96.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 24 | 100.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 28 | 96.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 32 | 96.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 36 | 96.6 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 44 | 96.6 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 48 | 96.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 52 | 96.4 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 48 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 36 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 16 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 12 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 40 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 8 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Day 7 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 44 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 4 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 28 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 24 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 52 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 32 | 100.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints | Week 20 | 100.0 Percentage of participants |
Comparison: Week 40: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [-10.72, 1.19]
Comparison: Week 40: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-8.07, 0.92]
Comparison: Week 52: Faricimab Q12W vs. Ranibizumab Q4W
Comparison: Week 52: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-8.07, 0.92]
Secondary
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 16 | 4.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 4 | 4.2 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 36 | 4.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 20 | 4.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Day 7 | 4.2 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 32 | 4.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 24 | 4.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 44 | 5.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 28 | 4.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 8 | 8.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 52 | 4.8 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Baseline | 8.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 12 | 4.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 48 | 4.8 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 40 | 0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 40 | 3.6 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Baseline | 3.2 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Day 7 | 0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 4 | 3.2 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 8 | 6.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 12 | 6.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 16 | 3.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 20 | 6.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 24 | 6.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 28 | 3.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 32 | 3.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 36 | 3.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 44 | 3.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 48 | 3.6 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 52 | 3.6 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 16 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 48 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 36 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 12 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 8 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 40 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 4 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Baseline | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 44 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 24 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Day 7 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 28 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 20 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 52 | 0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints | Week 32 | 0 Percentage of participants |
Comparison: Week 40: Faricimab Q12W vs. Ranibizumab Q4W
Comparison: Week 40: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-0.92, 8.07]
Comparison: Week 52: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [-1.19, 10.72]
Comparison: Week 52: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [-0.92, 8.07]
Secondary
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 32 | 60.9 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 4 | 45.8 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 48 | 57.1 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 28 | 56.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Day 7 | 20.8 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 52 | 57.1 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 16 | 52.2 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Baseline | 12.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 36 | 59.1 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 24 | 56.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 12 | 43.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 40 | 61.9 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 20 | 47.8 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 8 | 41.7 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 44 | 50.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 16 | 70.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 28 | 73.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 32 | 70.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 36 | 75.9 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 40 | 78.6 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 44 | 72.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 48 | 75.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 52 | 71.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Baseline | 22.6 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Day 7 | 45.2 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 4 | 51.6 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 8 | 70.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 12 | 73.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 24 | 70.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 20 | 73.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 16 | 43.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 4 | 25.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 40 | 40.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 28 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 8 | 20.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 36 | 43.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 24 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 12 | 31.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 52 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 32 | 43.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Baseline | 18.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 48 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 20 | 50.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Day 7 | 18.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints | Week 44 | 37.5 Percentage of participants |
Comparison: Week 40: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [0.76, 43.05]
Comparison: Week 40: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [19.56, 57.59]
Comparison: Week 52: Faricimab Q12W vs. Ranibizumab Q4W80% CI: [-1.14, 40.43]
Comparison: Week 52: Faricimab Q16W vs. Ranibizumab Q4W80% CI: [14.95, 52.91]
Secondary
Percentage of Participants With No Cysts at Specified Timepoints
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 16 | 91.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 4 | 87.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 36 | 77.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 20 | 91.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Day 7 | 65.2 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 32 | 82.6 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 24 | 73.9 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 44 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 28 | 95.7 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 8 | 83.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 52 | 100.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Baseline | 33.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 12 | 91.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 48 | 95.2 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Cysts at Specified Timepoints | Week 40 | 85.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 40 | 78.6 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Baseline | 48.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Day 7 | 83.9 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 4 | 87.1 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 8 | 83.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 12 | 83.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 16 | 83.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 20 | 80.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 24 | 76.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 28 | 70.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 32 | 76.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 36 | 79.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 44 | 72.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 48 | 85.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Cysts at Specified Timepoints | Week 52 | 78.6 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 16 | 75.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 48 | 87.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 36 | 68.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 12 | 68.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 8 | 86.7 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 40 | 80.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 4 | 87.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Baseline | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 44 | 87.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 24 | 68.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Day 7 | 75.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 28 | 68.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 20 | 68.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 52 | 87.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Cysts at Specified Timepoints | Week 32 | 75.0 Percentage of participants |
Secondary
Percentage of Participants With No Intraretinal Fluid at Specified Timepoints
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Intraretinal fluid was defined as the presence of fluid within the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 16 | 47.8 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 4 | 29.2 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 36 | 31.8 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 20 | 43.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 52 | 38.1 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 32 | 26.1 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 24 | 30.4 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 44 | 55.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 28 | 26.1 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 8 | 33.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Baseline | 4.2 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Day 7 | 21.7 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 12 | 39.1 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 48 | 38.1 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 40 | 38.1 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 40 | 57.1 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Baseline | 29.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Day 7 | 38.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 4 | 48.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 8 | 46.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 12 | 43.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 16 | 50.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 20 | 53.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 24 | 50.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 28 | 53.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 32 | 50.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 36 | 44.8 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 44 | 48.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 48 | 53.6 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 52 | 35.7 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 16 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 48 | 62.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 36 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 12 | 37.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 8 | 26.7 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 40 | 33.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 4 | 50.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Baseline | 18.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 44 | 43.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 24 | 31.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Day 7 | 25.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 28 | 31.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 20 | 18.8 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 52 | 62.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Intraretinal Fluid at Specified Timepoints | Week 32 | 31.3 Percentage of participants |
Secondary
Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 16 | 8.7 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 4 | 8.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 36 | 4.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 20 | 13.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Day 7 | 13.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 32 | 13.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 24 | 13.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 44 | 5.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 28 | 13.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 8 | 8.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 52 | 14.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Baseline | 8.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 12 | 8.7 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 48 | 9.5 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 40 | 4.8 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 40 | 21.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Baseline | 29.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Day 7 | 29.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 4 | 22.6 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 8 | 23.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 12 | 26.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 16 | 23.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 20 | 23.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 24 | 23.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 28 | 20.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 32 | 23.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 36 | 20.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 44 | 17.2 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 48 | 17.9 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 52 | 14.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 16 | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 48 | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 36 | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 12 | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 8 | 13.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 40 | 13.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 4 | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Baseline | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 44 | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 24 | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Day 7 | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 28 | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 20 | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 52 | 12.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints | Week 32 | 12.5 Percentage of participants |
Secondary
Percentage of Participants With No Subretinal Fluid at Specified Timepoints
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Population: Efficacy population: participants grouped according to their assigned treatment. This analysis of observed data included participants with non-missing assessments at each timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 16 | 87.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 4 | 70.8 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 36 | 68.2 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 20 | 69.6 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Day 7 | 39.1 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 32 | 69.6 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 24 | 65.2 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 44 | 80.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 28 | 91.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 8 | 83.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 52 | 81.0 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Baseline | 20.8 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 12 | 91.3 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 48 | 71.4 Percentage of participants |
| 6 mg Faricimab Q12W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 40 | 81.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 40 | 89.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Baseline | 12.9 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Day 7 | 29.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 4 | 77.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 8 | 86.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 12 | 90.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 16 | 96.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 20 | 70.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 24 | 66.7 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 28 | 70.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 32 | 80.0 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 36 | 72.4 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 44 | 75.9 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 48 | 64.3 Percentage of participants |
| 6 mg Faricimab Q16W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 52 | 89.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 16 | 75.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 48 | 87.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 36 | 81.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 12 | 75.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 8 | 80.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 40 | 86.7 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 4 | 62.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Baseline | 25.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 44 | 81.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 24 | 75.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Day 7 | 31.3 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 28 | 75.0 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 20 | 87.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 52 | 87.5 Percentage of participants |
| 0.5 mg Ranibizumab Q4W | Percentage of Participants With No Subretinal Fluid at Specified Timepoints | Week 32 | 68.8 Percentage of participants |
Secondary
Safety Summary: Number and Percentage of Participants With at Least One Adverse Event
This safety summary reports the number and percentage of participants who experienced at least one adverse event (AE) during the study. The investigator independently assessed the seriousness and severity for each AE. Severity was graded according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Severity and seriousness are not synonymous; regardless of severity, some AEs may have also met seriousness criteria.
Time frame: From Baseline until 28 days after the last dose of study drug (up to 52 weeks)
Population: Safety Population: participants who received at least one dose of the study treatment, grouped according to treatment received.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 6 mg Faricimab Q12W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | AE Leading to Dose Modification/Interruption | 2 Participants |
| 6 mg Faricimab Q12W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Serious Ocular AE | 0 Participants |
| 6 mg Faricimab Q12W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Ocular AE in the Fellow Eye | 6 Participants |
| 6 mg Faricimab Q12W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | AE Leading to Withdrawal from Treatment | 0 Participants |
| 6 mg Faricimab Q12W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Serious Non-Ocular AE | 4 Participants |
| 6 mg Faricimab Q12W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Any Adverse Event (AE) | 18 Participants |
| 6 mg Faricimab Q12W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | SAE Leading to Withdrawal from Treatment | 0 Participants |
| 6 mg Faricimab Q12W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Serious AE (SAE) | 4 Participants |
| 6 mg Faricimab Q12W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Ocular AE in the Study Eye | 9 Participants |
| 6 mg Faricimab Q12W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | SAE Leading to Dose Modification/Interruption | 1 Participants |
| 6 mg Faricimab Q12W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Non-Ocular AE | 14 Participants |
| 6 mg Faricimab Q16W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Serious Non-Ocular AE | 3 Participants |
| 6 mg Faricimab Q16W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Any Adverse Event (AE) | 23 Participants |
| 6 mg Faricimab Q16W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Serious AE (SAE) | 3 Participants |
| 6 mg Faricimab Q16W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | SAE Leading to Withdrawal from Treatment | 0 Participants |
| 6 mg Faricimab Q16W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | SAE Leading to Dose Modification/Interruption | 0 Participants |
| 6 mg Faricimab Q16W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Serious Ocular AE | 0 Participants |
| 6 mg Faricimab Q16W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | AE Leading to Withdrawal from Treatment | 0 Participants |
| 6 mg Faricimab Q16W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | AE Leading to Dose Modification/Interruption | 0 Participants |
| 6 mg Faricimab Q16W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Ocular AE in the Study Eye | 11 Participants |
| 6 mg Faricimab Q16W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Ocular AE in the Fellow Eye | 5 Participants |
| 6 mg Faricimab Q16W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Non-Ocular AE | 20 Participants |
| 0.5 mg Ranibizumab Q4W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Ocular AE in the Fellow Eye | 6 Participants |
| 0.5 mg Ranibizumab Q4W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | AE Leading to Dose Modification/Interruption | 0 Participants |
| 0.5 mg Ranibizumab Q4W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | SAE Leading to Withdrawal from Treatment | 0 Participants |
| 0.5 mg Ranibizumab Q4W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Any Adverse Event (AE) | 13 Participants |
| 0.5 mg Ranibizumab Q4W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Ocular AE in the Study Eye | 8 Participants |
| 0.5 mg Ranibizumab Q4W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Serious AE (SAE) | 0 Participants |
| 0.5 mg Ranibizumab Q4W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Serious Non-Ocular AE | 0 Participants |
| 0.5 mg Ranibizumab Q4W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Serious Ocular AE | 0 Participants |
| 0.5 mg Ranibizumab Q4W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | Non-Ocular AE | 9 Participants |
| 0.5 mg Ranibizumab Q4W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | AE Leading to Withdrawal from Treatment | 0 Participants |
| 0.5 mg Ranibizumab Q4W | Safety Summary: Number and Percentage of Participants With at Least One Adverse Event | SAE Leading to Dose Modification/Interruption | 0 Participants |